Ramucirumab_product_DataBase

Bioactivity	Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor[1][2].
Invitro	Ramucirumab (10 μg/mL) impedes both VEGF- and tumor-driven cord formation[3].Ramucirumab does not cross react with mouse VEGFR2[3].
Name	Ramucirumab
CAS	947687-13-0
Formula	C6374H9864N1692O1996S46
Molar Mass	143609.63
Appearance	Liquid
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53. [2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5. [3]. Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget. 2019 Sep 17;10(53):5523-5533.

PeptideDB